Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | TARS1 | P26639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6441420 | 0.99 | F2 (0.62) | F2PRSS1ROCK1PLGF10 | |
| SCHEMBL6437265 | 0.92 | F2 (0.74) | F2PRSS1ROCK1F10 | |
| SCHEMBL6438654 | 0.89 | PLAT (0.56) | F2PRSS1ROCK1TARS1 | |
| Hydrochloric Acid SCHEMBL6438645 | 0.88 | PLAT (0.55) | F2PRSS1ROCK1F10TARS1 | |
| SCHEMBL6435934 | 0.86 | F2 (0.74) | F2PRSS1F10 | |
| Hydrochloric Acid SCHEMBL6440020 | 0.82 | F2 (0.84) | F2PRSS1PLGF10HPN | |
| Hydrochloric Acid SCHEMBL6439337 | 0.80 | PLAT (0.51) | F2PRSS1ROCK1F10TARS1 | |
| SCHEMBL7984105 | 0.79 | BACE1 (0.62) | F2 | |
| Hydrochloric Acid SCHEMBL6439383 | 0.78 | F2 (0.60) | F2PRSS1PLGF10 | |
| Hydrochloric Acid SCHEMBL6436817 | 0.77 | F2 (0.99) | F2PRSS1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | F2 1/4885PRSS1 857/4885ROCK1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.